IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 151-175 out of 1376.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

Public Release: 8-Jun-2016
ACS Nano
Drug candidate shrinks tumor when delivered by plant virus nanoparticle
In a pair of firsts, researchers at Case Western Reserve University and Massachusetts Institute of Technology have shown that the drug candidate phenanthriplatin can be more effective than an approved drug in vivo, and that a plant-virus-based carrier successfully delivers a drug in vivo.
NIH/National Cancer Institute, National Science Foundation, Mt. Sinai Foundation, National Institutes of Health

Contact: Kevin Mayhood
Case Western Reserve University

Public Release: 8-Jun-2016
American Journal of Pathology
New study lays groundwork for potential new anti-cancer therapy
Identifying the cell of origin is crucial to understanding how a tumor develops and metastasizes and for developing targeted therapies. Researchers have found evidence supporting a lymphatic endothelium origin for angiomyolipoma (AML) and lymphangioleiomyomatosis (LAM), two related tumors with previously unknown cellular origins. Furthermore, the newly identified lymphatic endothelial lineage shows translational potential for pharmaceutical treatment. Their findings are published in The American Journal of Pathology.
National Institutes of Health

Contact: Eileen Leahy
Elsevier Health Sciences

Public Release: 8-Jun-2016
New England Journal of Medicine
Sanger Institute: Landmark study shows AML is at least 11 different diseases
Patients with acute myeloid leukemia (AML) could be separated genomically into at least 11 major groups, each with different constellations of genetic changes and distinctive clinical features. This genetic complexity helps explain why AML shows such variability in survival rates among patients. Full knowledge of the genetic make-up of a patient's leukemia substantially improved the ability to predict whether that patient would be cured with current treatments.
Wellcome Trust, Bundesministerium fur Bildungund Forschung, Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft, European Hematology Association, Amgen, Kay Kendall Leukaemia Fund

Contact: Sam Wynne
Wellcome Trust Sanger Institute

Public Release: 8-Jun-2016
Journal of Molecular Diagnostics
New mutation-testing technology has potential to guide targeted lung and colorectal cancer therapies
A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The Journal of Molecular Diagnostics.
NIH/National Cancer Institute, University of Virginia Cancer Center

Contact: Eileen Leahy
Elsevier Health Sciences

Public Release: 8-Jun-2016
Chemical & Engineering News
Cancer researchers take on an old foe
In the annals of cancer research, a protein known as KRas has become notorious. Part of a family of proteins implicated in 30 percent of cancers, KRas is considered a highly desirable but defiant drug target. Scientists have resuscitated efforts to crack its structure and find drugs to disable it. The cover story of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, reports on the latest efforts to fight KRas.

Contact: Michael Bernstein
American Chemical Society

Public Release: 8-Jun-2016
Whole-exome sequencing predicts which bladder cancers and cell lines respond to cisplatin
University of Colorado Cancer Center study published online in Oncogene describes mutational landscape of bladder cancer cell lines, demonstrates that alterations in these cells lines do indeed match changes in samples of human bladder cancer and shows genes and gene pathways that may be functionally involved in the ability of bladder cancer to resist therapy.
National Institutes of Health

Contact: Garth Sundem
University of Colorado Anschutz Medical Campus

Public Release: 8-Jun-2016
Clinical Cancer Research
New compound shows potential for triple-negative breast cancer
Researchers at the University of Michigan have identified a promising new compound for targeting one of the most aggressive types of breast cancer.
Breast Cancer Research Foundation, Metavivor Foundation, Avon Foundation, Kathy Bruk Pearch Research Fund

Contact: Nicole Fawcett
University of Michigan Health System

Public Release: 7-Jun-2016
American Society for Pharmacology and Experimental Therapeutics
Benefits to timing chemotherapy to body's 'awake' time
Not a morning person? Neither are your kidneys. Research from the Washington State University College of Pharmacy suggests there may be benefits to timing chemotherapy in cancer patients to the time of day the body is 'most awake.'

Contact: Shobhan Gaddameedhi
Washington State University

Public Release: 7-Jun-2016
New approach to MRI imaging links saturated fats to breast cancer in postmenopausal women
High saturated fats in breast tissue may be an indicator of cancer in postmenopausal women, a study shows.
National Institutes of Health

Contact: Jamie Liptack
NYU Langone Medical Center / New York University School of Medicine

Public Release: 7-Jun-2016
Saturated fatty acids linked to breast cancer in postmenopausal women
Fatty acids in the breast may be useful indicators of cancer in postmenopausal women, according to a new study published online in the journal Radiology. The results may help researchers determine the underlying mechanisms behind breast cancer development in some patients.
National Institutes of Health

Contact: Linda Brooks
Radiological Society of North America

Public Release: 7-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Early detection, smaller cancer among benefits of skin cancer screening at PCP visits
Skin cancer screenings performed by primary care physicians (PCPs) during routine office visits improve the detection of potentially deadly melanomas and find them in earlier stages, according to new research from the University of Pittsburgh School of Medicine. The results were presented today at the 52nd annual American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
National Cancer Institute

Contact: Allison Hydzik
University of Pittsburgh Schools of the Health Sciences

Public Release: 7-Jun-2016
Journal of Medical Devices
Chemical 'sponges' designed to soak up toxic cancer-fighting drugs after targeting tumors
Researchers are creating materials for a cancer treatment system that can limit the side effects of chemotherapy drugs by quickly removing them from the body after use.

Contact: Glenn Roberts Jr.
DOE/Lawrence Berkeley National Laboratory

Public Release: 7-Jun-2016
Nature Communications
New types of blood cancer discovered in children
Through a detailed study of leukaemia cells from more than 200 children, a research group at Lund University in Sweden has discovered two new types of childhood leukaemia. Using next-generation sequencing technology (NGS), the researchers were able to study the genome of cancer cells, which is how they discovered the new types of cancer.
Swedish Childhood Cancer Foundation, Swedish Cancer Society, Swedish Research Council, Faculty of Medicine at Lund University and Region Skåne

Contact: Cecilia Schubert
Lund University

Public Release: 7-Jun-2016
PLOS Computational Biology
Scientists use modelling to show the role of metabolism and signaling in cancer metastasis
Researchers have built a model to investigate the metastasis of cancer by examining the metabolism of breast epithelial cells and look at the role of signaling. This research, published in PLOS Computational Biology, may contribute to the development of cell specific anti-cancer interventions.

Contact: Ottar Rolfsson

Public Release: 7-Jun-2016
Journal of Nuclear Medicine
Predicting advanced prostate cancer outcomes with NaF-PET/CT
A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium fluoride (Na-F-18) positron emission tomography/computed tomography (NaF-PET/CT) accurately detects bone metastases in patients with advanced prostate cancer, and follow-up scans over time correlate clearly with clinical outcomes and patient survival.
NIH/National Cancer Institute

Contact: Laurie Callahan
Society of Nuclear Medicine

Public Release: 7-Jun-2016
Journal of National Cancer Institute
Survival correlation for low versus high enrolling institutions for patients with LA-NSCLC
A secondary analysis of NRG Oncology's clinical trial RTOG 0617, published in the Journal of the National Cancer Institute, was initiated in an effort to evaluate the effect of institution accrual volume on clinical outcomes among patients receiving chemoradiation for locally advanced non-small cell lung cancer (LA-NSCLC).
NIH/National Cancer Institute, Bristol-Myers Squibb

Contact: Angela LaPenta
NRG Oncology

Public Release: 7-Jun-2016
Study questions cancer link with bone growth factor for spinal surgery
Adding to previous evidence, a study based on a statewide cancer database shows no increase in cancer risk in patients undergoing spinal fusion surgery with the bone-promoting growth factor recombinant human bone morphogenetic protein. The study appears in Spine, published by Wolters Kluwer.

Contact: Connie Hughes
Wolters Kluwer Health

Public Release: 6-Jun-2016
Blood-born molecules could predict those who will develop liver cancer
A panel of microRNAs from blood samples may predict patients at high risk of developing a common liver cancer from hepatitis B virus infection.

Contact: Edyta Zielinska
Thomas Jefferson University

Public Release: 6-Jun-2016
American Society of Clinical Oncology Annual Meeting
Study may help reassure women taking tamoxifen for breast cancer
A study presented at ASCO may help reassure patients who worry the breast cancer drug tamoxifen could increase their risk of uterine cancer.
National Cancer Institute

Contact: Jim Ritter
Loyola University Health System

Public Release: 6-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Cancer drug trial success
The successful results of a University of Liverpool led drug trial aimed at developing new therapeutic approaches to cancer have been presented at two American medical conferences.

Contact: Nicola Frost
University of Liverpool

Public Release: 6-Jun-2016
Journal of Clinical Oncology
Methotrexate exposure impacts cognitive processes cancer survivors need to multitask
St. Jude Children's Research Hospital reports that higher blood concentrations of methotrexate during cancer treatment are associated with brain changes and impaired executive function in survivors of pediatric leukemia.
NIH/National Institute of Mental Health, ALSAC

Contact: Frannie Marmorstein
St. Jude Children's Research Hospital

Public Release: 6-Jun-2016
Journal of the American Chemical Society
A new approach to chemical synthesis
MIT chemists have devised a new way to synthesize communesins -- fungal compounds with anti-cancer potential.
National Institutes of Health, National Science Foundation

Contact: Sarah McDonnell
Massachusetts Institute of Technology

Public Release: 6-Jun-2016
Annals of the New York Academy of Sciences
War and peace in the human gut: Probing the microbiome
In research appearing in the current issue of Annals of the New York Academy of Science, Aktipis and her colleagues Helen Wasielewski (ASU's Department of Psychology), and Joe Alcock, (at the University of New Mexico Department of Emergency Medicine), examine the role of microbes in the gut. Their study explores how dietary choices promote cooperation or might fuel conflict between gut microbes and the humans they interact with, maintaining health or encouraging the onset of disease.

Contact: Joseph Caspermeyer
Arizona State University

Public Release: 6-Jun-2016
JAMA Oncology
Personalized medicine leads to better outcomes for patients with cancer
In a meta-analysis of hundreds of clinical trials involving thousands of patients, researchers at University of California San Diego School of Medicine report that therapeutic approaches using precision medicine, which emphasizes the use of individual genetics to refine cancer treatment, showed improved response and longer periods of disease remission, even in phase I trials.
Joan and Irwin Jacobs Fund

Contact: Yadira Galindo
University of California - San Diego

Public Release: 6-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Moffitt researchers present phase 1 study results of selinexor combination therapy; multiple myeloma
Moffitt Cancer Center will present results from a phase 1 study of selinexor in combination with liposomal doxorubicin and dexamethasone in patients with relapsed and refractory multiple myeloma. The findings will be discussed Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.

Contact: Lisa Chillura
H. Lee Moffitt Cancer Center & Research Institute

Showing releases 151-175 out of 1376.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

  Search News Releases